Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 8, 2004, Pages 1355-1360

  Wang, Sophia S ^a   Trunk, Marcus ^b   Schiffman, Mark ^a   Herrero, Rolando ^c   Sherman, Mark E ^a   Burk, Robert D ^d   Hildesheim, Allan ^a   Bratti, M Concepcion ^c   Wright, Tom ^e   Rodriguez, Ana Cecilia ^c   Chen, Sabrina ^f   Reichert, Anja ^b   Von Knebel Doeberitz, Christina ^b   Ridder, Ruediger ^b   Von Knebel Doeberitz, Magnus ^g  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MTM Laboratories   (Germany)

^c Proyecto Epidemiologico Guanacaste   (Costa Rica)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e Surgeons of Columbia University ^*  (United States)

^f INFORMATION MANAGEMENT SERVICES INC   (United States)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; TUMOR MARKER; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; COSTA RICA; DIAGNOSTIC VALUE; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS DETECTION; WART VIRUS; ADOLESCENT; CASE CONTROL STUDY; COHORT ANALYSIS; COLPOSCOPY; COMPARATIVE STUDY; INCIDENCE; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; PATHOLOGY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VALIDATION STUDY; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COHORT STUDIES; COLPOSCOPY; COSTA RICA; DNA, VIRAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; INDICATORS AND REAGENTS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 7044231257     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
2. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
3. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5.
4. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-8.
5. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
6. ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia. Pathol Int 2002;52:375-83.
7. Agoff SN, Lin P, Morihara J, Mao C, Kiviat NB, Koutsky LA. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 2003;16:665-73.
8. INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 2003;56:56-63.
9. INK4A in liquid-based specimens (SurePath) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol 2002;27:365-70.
10. INK4A antigen in thin-layer, liquid-based specimens. Acta Cytol 2002;46:25-9.
11. Stanley MA. Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res 2002;89:241-8.
12. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-74.
13. Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica 1997;1:362-75.
14. Castle PE, Schiffman M, Gravitt PE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002;68:417-23.
15. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
16. INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26:1389-99.
17. Gage JR, Meyers C, Wettstein FO. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J Virol 1990;64:723-30.
18. INK4A are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001;25:884-91.
19. Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 2001;8:83-92.
20. von Knebel DM. New markers for cervical dysplasia to visualize the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229-42.